Overview We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. Cortisol plays a significant role in the bodys response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon ...
Q2 FY2026 — expected 2026-09-20
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001628280-26-011091 | EDGAR | 58K words |
| 2025-02-26 | 2024-12-31 | 0001628280-25-008167 | EDGAR | — |
| 2024-02-15 | 2023-12-31 | 0001628280-24-005055 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001628280-23-005581 | EDGAR | — |
| 2022-02-15 | 2021-12-31 | 0001628280-22-002714 | EDGAR | — |
| 2021-02-23 | 2020-12-31 | 0001628280-21-002861 | EDGAR | — |
| 2020-02-24 | 2019-12-31 | 0001628280-20-002122 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001628280-19-001879 | EDGAR | — |
| 2018-02-28 | 2017-12-31 | 0001564590-18-003840 | EDGAR | — |
| 2017-03-06 | 2016-12-31 | 0001564590-17-003493 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001628280-25-048841 | EDGAR | 27K words |
| 2025-07-31 | 2025-06-30 | 0001628280-25-037005 | EDGAR | — |
| 2025-05-05 | 2025-03-31 | 0001628280-25-022173 | EDGAR | — |
| 2024-10-30 | 2024-09-30 | 0001628280-24-044322 | EDGAR | — |
| 2024-07-29 | 2024-06-30 | 0001628280-24-033284 | EDGAR | — |
| 2024-05-01 | 2024-03-31 | 0001628280-24-019610 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0001628280-23-035988 | EDGAR | — |
| 2023-08-02 | 2023-06-30 | 0001628280-23-026768 | EDGAR | — |
| 2023-05-03 | 2023-03-31 | 0001628280-23-015236 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001628280-22-028203 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-020731 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001628280-22-012662 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001193125-26-123543 | EDGAR | 2K words |
| 2026-02-24 | 0001628280-26-011080 | EDGAR | — |
| 2026-02-19 | 0001193125-26-059551 | EDGAR | — |
| 2026-01-22 | 0001193125-26-018704 | EDGAR | — |
| 2025-12-31 | 0001193125-25-338184 | EDGAR | — |
| 2025-11-04 | 0001628280-25-048814 | EDGAR | — |
| 2025-10-14 | 0001193125-25-237834 | EDGAR | — |
| 2025-10-06 | 0001193125-25-231963 | EDGAR | — |
| 2025-09-10 | 0001193125-25-199706 | EDGAR | — |
| 2025-07-31 | 0001628280-25-036999 | EDGAR | — |
174 total filings indexed. 142 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001088856 |
| Ticker | CORT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.corcept.com |
| Listed | 2004-04-14 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report